Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Revance Therapeutics

Nasdaq:RVNC
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
RVNC
Nasdaq
$855M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The last earnings update was 42 days ago. More info.


Add to Portfolio Compare Print
  • Revance Therapeutics has significant price volatility in the past 3 months.
RVNC Share Price and Events
7 Day Returns
19%
NasdaqGM:RVNC
4.6%
US Pharmaceuticals
2.4%
US Market
1 Year Returns
4%
NasdaqGM:RVNC
-2%
US Pharmaceuticals
-10%
US Market
RVNC Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Revance Therapeutics (RVNC) 19% -18.2% -9% 4% -27.7% -33.1%
US Pharmaceuticals 4.6% -3.1% -7.9% -2% 10% 5.4%
US Market 2.4% -11% -19.4% -10% 9.6% 21.1%
1 Year Return vs Industry and Market
  • RVNC outperformed the Pharmaceuticals industry which returned -2% over the past year.
  • RVNC outperformed the Market in United States of America which returned -10% over the past year.
Price Volatility
RVNC
Industry
5yr Volatility vs Market

Value

 Is Revance Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Revance Therapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Revance Therapeutics.

NasdaqGM:RVNC Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 11 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.1%
Perpetual Growth Rate 10-Year US Government Bond Rate 1.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGM:RVNC
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 1.7%
Equity Risk Premium S&P Global 5.4%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.63
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.629 (1 + (1- 21%) (3.43%))
0.763
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.74% + (0.8 * 5.44%)
6.09%

Discounted Cash Flow Calculation for NasdaqGM:RVNC using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Revance Therapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

NasdaqGM:RVNC DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 6.09%)
2020 -244.30 Analyst x2 -230.27
2021 -205.59 Analyst x2 -182.65
2022 -70.06 Analyst x2 -58.67
2023 50.53 Analyst x2 39.88
2024 197.87 Analyst x2 147.22
2025 339.60 Est @ 71.63% 238.16
2026 511.64 Est @ 50.66% 338.21
2027 695.75 Est @ 35.98% 433.50
2028 874.63 Est @ 25.71% 513.67
2029 1,036.61 Est @ 18.52% 573.84
Present value of next 10 years cash flows $1,812.00
NasdaqGM:RVNC DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $1,036.61 × (1 + 1.74%) ÷ (6.09% – 1.74%)
$24,233.71
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $24,233.71 ÷ (1 + 6.09%)10
$13,415.09
NasdaqGM:RVNC Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $1,812.00 + $13,415.09
$15,227.09
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $15,227.09 / 57.03
$267
NasdaqGM:RVNC Discount to Share Price
Calculation Result
Value per share (USD) From above. $267.00
Current discount Discount to share price of $15.00
= -1 x ($15.00 - $267.00) / $267.00
94.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Revance Therapeutics is available for.
Intrinsic value
>50%
Share price is $15 vs Future cash flow value of $267
Current Discount Checks
For Revance Therapeutics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Revance Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Revance Therapeutics's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Revance Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Revance Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:RVNC PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-3.67
NasdaqGM:RVNC Share Price ** NasdaqGM (2020-04-07) in USD $15
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 24 Publicly-Listed Pharmaceuticals Companies 20.33x
United States of America Market PE Ratio Median Figure of 2,948 Publicly-Listed Companies 12.95x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Revance Therapeutics.

NasdaqGM:RVNC PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:RVNC Share Price ÷ EPS (both in USD)

= 15 ÷ -3.67

-4.09x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Revance Therapeutics is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • Revance Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Revance Therapeutics's expected growth come at a high price?
Raw Data
NasdaqGM:RVNC PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.09x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 11 Analysts
50.1%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.91x
United States of America Market PEG Ratio Median Figure of 2,010 Publicly-Listed Companies 0.92x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Revance Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Revance Therapeutics's assets?
Raw Data
NasdaqGM:RVNC PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $4.31
NasdaqGM:RVNC Share Price * NasdaqGM (2020-04-07) in USD $15
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 181 Publicly-Listed Pharmaceuticals Companies 2.42x
United States of America Market PB Ratio Median Figure of 5,162 Publicly-Listed Companies 1.26x
NasdaqGM:RVNC PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:RVNC Share Price ÷ Book Value per Share (both in USD)

= 15 ÷ 4.31

3.48x

* Primary Listing of Revance Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Revance Therapeutics is overvalued based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess Revance Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Revance Therapeutics has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Revance Therapeutics expected to perform in the next 1 to 3 years based on estimates from 11 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
50.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Revance Therapeutics expected to grow at an attractive rate?
  • Revance Therapeutics's earnings growth is expected to exceed the low risk savings rate of 1.7%.
Growth vs Market Checks
  • Revance Therapeutics's earnings growth is expected to exceed the United States of America market average.
  • Revance Therapeutics's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:RVNC Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:RVNC Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 11 Analysts 50.1%
NasdaqGM:RVNC Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 11 Analysts 52.2%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 27.3%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:RVNC Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 11 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:RVNC Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 547 197 7
2023-12-31 392 66 7
2022-12-31 219 4 -78 8
2021-12-31 106 -72 -200 10
2020-12-31 9 -185 -246 11
2020-04-08
NasdaqGM:RVNC Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 0 -106 -159
2019-09-30 1 -104 -155
2019-06-30 3 -97 -146
2019-03-31 4 -105 -143
2018-12-31 4 -104 -143
2018-09-30 3 -102 -138
2018-06-30 1 -98 -136
2018-03-31 0 -85 -128
2017-12-31 0 -95 -121
2017-09-30 0 -80 -111
2017-06-30 0 -73 -99
2017-03-31 0 -65 -97

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Revance Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Revance Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:RVNC Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 11 Analyst Estimates (S&P Global) See Below

All data from Revance Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:RVNC Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 3.09 3.40 2.45 4.00
2023-12-31 1.06 1.65 0.38 3.00
2022-12-31 -1.66 -0.60 -2.71 4.00
2021-12-31 -3.42 -2.87 -3.85 5.00
2020-12-31 -4.27 -3.85 -4.61 5.00
2020-04-08
NasdaqGM:RVNC Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -3.67
2019-09-30 -3.76
2019-06-30 -3.71
2019-03-31 -3.80
2018-12-31 -3.94
2018-09-30 -3.94
2018-06-30 -4.05
2018-03-31 -4.03
2017-12-31 -4.01
2017-09-30 -3.81
2017-06-30 -3.44
2017-03-31 -3.41

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Revance Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Revance Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Revance Therapeutics has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Revance Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Revance Therapeutics's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Revance Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Revance Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Revance Therapeutics's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Revance Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Revance Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:RVNC Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 0.41 -159.43 68.81 96.06
2019-09-30 0.81 -154.72 62.10 95.40
2019-06-30 3.13 -146.14 59.52 91.41
2019-03-31 3.81 -142.84 58.66 88.76
2018-12-31 3.73 -142.57 53.86 92.50
2018-09-30 3.28 -137.86 57.69 82.67
2018-06-30 0.99 -135.68 52.69 82.46
2018-03-31 0.38 -128.47 48.56 77.89
2017-12-31 0.26 -120.59 37.40 80.36
2017-09-30 0.30 -111.48 37.91 66.59
2017-06-30 0.30 -98.81 36.27 55.24
2017-03-31 0.30 -96.54 34.67 52.13
2016-12-31 0.30 -89.27 34.38 45.08
2016-09-30 0.30 -84.56 34.18 47.51
2016-06-30 0.30 -85.76 32.51 50.23
2016-03-31 0.30 -77.96 31.85 45.34
2015-12-31 0.30 -73.48 30.39 42.23
2015-09-30 0.30 -65.59 28.18 36.50
2015-06-30 0.30 -60.40 27.65 32.09
2015-03-31 0.30 -56.89 26.15 29.89
2014-12-31 0.38 -62.92 24.24 28.19
2014-09-30 0.62 -49.18 21.65 26.10
2014-06-30 0.70 -48.00 18.50 23.78
2014-03-31 0.70 -38.28 17.28 23.46
2013-12-31 0.62 0.26 15.41 23.43
2013-09-30 0.43 -10.17 9.62 38.47

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Revance Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Revance Therapeutics has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Revance Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Revance Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Revance Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Revance Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Revance Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Revance Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Revance Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Revance Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Revance Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Revance Therapeutics Company Filings, last reported 3 months ago.

NasdaqGM:RVNC Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 225.49 0.00 290.12
2019-09-30 151.28 0.00 209.03
2019-06-30 188.54 0.00 241.89
2019-03-31 221.10 0.00 270.99
2018-12-31 145.62 0.00 175.81
2018-09-30 182.10 0.00 208.39
2018-06-30 209.86 0.00 233.73
2018-03-31 236.64 0.98 268.81
2017-12-31 268.85 1.87 282.90
2017-09-30 142.06 2.73 153.44
2017-06-30 159.41 3.55 165.55
2017-03-31 178.67 4.49 188.64
2016-12-31 177.07 5.35 185.53
2016-09-30 200.72 6.18 201.25
2016-06-30 215.78 6.97 216.94
2016-03-31 236.85 7.74 236.61
2015-12-31 253.25 8.48 252.30
2015-09-30 142.36 9.19 141.86
2015-06-30 148.84 9.88 135.30
2015-03-31 163.46 0.83 153.72
2014-12-31 176.37 3.54 171.03
2014-09-30 187.91 9.70 187.49
2014-06-30 198.51 11.75 203.31
2014-03-31 78.69 13.81 87.85
2013-12-31 -32.33 25.49 3.91
2013-09-30 -22.24 12.95 1.91
  • Revance Therapeutics has no debt.
  • Revance Therapeutics has no debt compared to 5 years ago when it was 1.5%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Revance Therapeutics has sufficient cash runway for 2.7 years based on current free cash flow.
  • Revance Therapeutics has sufficient cash runway for 1.2 years if free cash flow continues to grow at historical rates of 13.2% each year.
X
Financial health checks
We assess Revance Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Revance Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Revance Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Revance Therapeutics dividends. Estimated to be 0% next year.
If you bought $2,000 of Revance Therapeutics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Revance Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Revance Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:RVNC Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 11 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 2.9%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1935 Stocks 2.9%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.9%
United States of America Top 25% Dividend Yield 75th Percentile 5.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:RVNC Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 0.00 1.00
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2020-04-08

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Revance Therapeutics has not reported any payouts.
  • Unable to verify if Revance Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Revance Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Revance Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Revance Therapeutics's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Revance Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Revance Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Revance Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Revance Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mark Foley
COMPENSATION $17,707,071
AGE 54
TENURE AS CEO 0.5 years
CEO Bio

Mr. Mark J. Foley serves as President and Chief Executive Officer at Revance Therapeutics, Inc. since October 14, 2019. He served as the Managing Director of RWI Ventures from 2004 to 2018. Mr. Foley joined RWI Ventures in 2004. He has been Director at SI-BONE, Inc. since June 17, 2019. He has many years of operational and investment experience in the healthcare arena. He served as the Chief Executive Officer and President at ZELTIQ Aesthetics, Inc. from August 23, 2012 until April 28, 2017. Mr. Foley served as an Interim Chief Executive Officer and Interim President at ZELTIQ Aesthetics, Inc. from April 2012 to August 24, 2012 and also served as its Interim Chief Financial Officer since August 2012. Mr. Foley held a variety of senior operating roles in large public companies and venture-backed startups, including U.S. Surgical Corporation, Guidant Corporation and Devices for Vascular Intervention (acquired by Eli Lilly), Perclose (acquired by Abbott) and Ventrica (acquired by Medtronic), where he was the founder and CEO. Mr. Foley spent many years in senior operating roles at both large and small start-up medical device companies. He founded Ventrica, Inc. in 1998 and served as its President and Chief Executive Officer. He co-founded FlexCor and Amor-X. Mr. Foley served as a Director of Business Development at Perclose, Inc. and was responsible for overseeing its C.V. surgical business. He served as a Director of Sales for Asia at Perclose. Mr. Foley has an intimate understanding of all aspects of what it takes to make a startup company successful, as well as an extensive rolodex and strong personal relationships with many key influencers in the Bay Area. He held management positions at Guidant, DVI, U.S. Surgical, James River Corporation and American Cyanamid. He serves as Chairman of ULab, HintMD and Arrinex. Mr. Foley served as an Executive Chairman of Onpharma Inc. from August 2009 to March 2014. He served as the Executive Chairman at Zeltiq Aesthetics, Inc. from February 2015 until April 28, 2017. Mr. Foley served as an Executive Chairman at Zeltiq Aesthetics, Inc., from May 2009 to June 2010. He serves as a Director of Encapsule Medical Devices, LLC, FlexCor and Amor-X. He has been Director at Revance Therapeutics, Inc. since September 5, 2017. Mr. Foley has been a Director of Glaukos Corporation since July 2014. He serves as a Director of Chakshu, BaroSense, DermaCare and Voyage Medical. Mr. Foley served as a Director of Sonitus Medical, Inc. He served as a Director of Zeltiq Aesthetics, Inc., from July 2009 to April 28, 2017. He served as a Director of Therative, Inc. He has over 20 issued, published and pending patent applications. He is a co-chair of the Aesthetics Innovation Summit. Mr. Foley received a Bachelor of Arts degree from the University of Notre Dame.

CEO Compensation
  • Mark's compensation has increased whilst company is loss making.
  • Mark's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Revance Therapeutics management team in years:

1.4
Average Tenure
51
Average Age
  • The average tenure for the Revance Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

Mark Foley

TITLE
President
COMPENSATION
$18M
AGE
54
TENURE
0.5 yrs

Toby Schilke

TITLE
CFO & Principal Accounting Officer
COMPENSATION
$1M
AGE
44
TENURE
1.4 yrs

Abhay Joshi

TITLE
Chief Operating Officer
COMPENSATION
$2M
AGE
56
TENURE
4.3 yrs

Dustin Sjuts

TITLE
Chief Commercial Officer of Aesthetics & Therapeutics
COMPENSATION
$801K
TENURE
1.4 yrs

Dwight Moxie

TITLE
Senior Vice President
TENURE
0.2 yrs

Jeanie Herbert

TITLE
Senior Director of Investor Relations & Corporate Communications
TENURE
3.3 yrs

Taryn Conway

TITLE
Vice President of Marketing
TENURE
1 yrs

Justin Ford

TITLE
VP of Human Resources & Head of People
TENURE
2.8 yrs

Azita Nejad

TITLE
Senior Vice President of Technical Operations
TENURE
0.1 yrs

Roman Rubio

TITLE
Senior Vice President of Clinical Development
AGE
48
Board of Directors Tenure

Average tenure and age of the Revance Therapeutics board of directors in years:

4.5
Average Tenure
61.5
Average Age
  • The tenure for the Revance Therapeutics board of directors is about average.
Board of Directors

Angus Russell

TITLE
Independent Chairman
COMPENSATION
$210K
AGE
63
TENURE
6.1 yrs

Mark Foley

TITLE
President
COMPENSATION
$18M
AGE
54
TENURE
2.6 yrs

Bob Byrnes

TITLE
Independent Director
COMPENSATION
$188K
AGE
74
TENURE
15.7 yrs

Chris Nolet

TITLE
Independent Director
COMPENSATION
$256K
AGE
62
TENURE
0.8 yrs

Phyllis Gardner

TITLE
Independent Director
COMPENSATION
$173K
AGE
68
TENURE
13.3 yrs

Phil Vickers

TITLE
Independent Director
COMPENSATION
$173K
AGE
59
TENURE
5.2 yrs

Julian Gangolli

TITLE
Independent Director
COMPENSATION
$172K
AGE
61
TENURE
3.8 yrs

Jill Beraud

TITLE
Director
COMPENSATION
$237K
AGE
59
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Revance Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Revance Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Is Revance Therapeutics, Inc.'s (NASDAQ:RVNC) CEO Paid At A Competitive Rate?

This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … View our latest analysis for Revance Therapeutics How Does Dan Browne's Compensation Compare With Similar Sized Companies? … Thus we can conclude that Dan Browne receives more in total compensation than the median of a group of companies in the same market, and of similar size to Revance Therapeutics, Inc..

Simply Wall St -

How Does Investing In Revance Therapeutics, Inc. (NASDAQ:RVNC) Impact The Volatility Of Your Portfolio?

Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … If the future looks like the past, we could therefore consider it likely that the stock price will experience share price volatility that is roughly similar to the overall market. … What this means for you: Revance Therapeutics has a beta value quite close to that of the overall market.

Simply Wall St -

What Should You Know About Revance Therapeutics, Inc.'s (NASDAQ:RVNC) Earnings Trajectory?

Revance Therapeutics, Inc.'s (NASDAQ:RVNC) most recent earnings update in December 2018 … that losses became smaller relative to the prior year's level

Simply Wall St -

Investors Who Bought Revance Therapeutics Shares Five Years Ago Are Now Down 51%

Revance Therapeutics isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). … When a company doesn't make profits, we'd generally expect to see good revenue growth. … In the last half decade, Revance Therapeutics saw its revenue increase by 40% per year.

Simply Wall St -

What Kind Of Shareholder Appears On The Revance Therapeutics, Inc.'s (NASDAQ:RVNC) Shareholder Register?

If you want to know who really controls Revance Therapeutics, Inc. … Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. … We also tend to see lower insider ownership in companies that were previously publicly owned.

Simply Wall St -

Who Has Been Buying Revance Therapeutics, Inc. (NASDAQ:RVNC) Shares?

So we'll take a look at whether insiders have been buying or selling shares in Revance Therapeutics, Inc. … But logic dictates you should pay some attention to whether insiders are buying or selling shares. … Revance Therapeutics Insider Transactions Over The Last Year.

Simply Wall St -

Revance Therapeutics, Inc. (NASDAQ:RVNC): The Best Of Both Worlds

(NASDAQ:RVNC) is a company with exceptional fundamental characteristics. … Upon building up an investment case for a stock, we should look at various aspects. … In the case of RVNC, it

Simply Wall St -

Is Revance Therapeutics, Inc.'s (NASDAQ:RVNC) Balance Sheet A Threat To Its Future?

However, it also faces higher cost of capital given interest cost is generally lower than equity. … Is RVNC growing fast enough to value financial flexibility over lower cost of capital. … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital

Simply Wall St -

Revance Therapeutics Inc (NASDAQ:RVNC): What Does Its Beta Value Mean For Your Portfolio?

Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … While we should keep in mind that Warren Buffett has cautioned that 'Volatility is far from synonymous with risk', beta is still a useful factor to consider.

Simply Wall St -

Is Revance Therapeutics Inc (NASDAQ:RVNC) Overpaying Its CEO?

This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does Dan Browne's Compensation Compare With Similar Sized Companies. … We examined companies with market caps from US$400m to US$1.6b, and discovered that the median CEO compensation of that group was US$2m.

Simply Wall St -

Company Info

Description

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI) which competed phase 3 clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; in phase 2 clinical trials to treat adult upper limb spasticity and plantar fasciitis, and in pre-clinical trials to treat chronic migraine. It is also developing DAXI for forehead lines, lateral canthal lines, and upper facial lines that is in phase 2 clinical trials; DaxibotulinumtoxinA Topical for therapeutic and aesthetic applications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration agreement with Mylan Ireland Limited for the development, manufacture, and commercialization of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark, California.

Details
Name: Revance Therapeutics, Inc.
RVNC
Exchange: NasdaqGM
Founded: 1999
$855,452,295
57,030,153
Website: http://www.revance.com
Address: Revance Therapeutics, Inc.
7555 Gateway Boulevard,
Newark,
California, 94560,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM RVNC Common Stock Nasdaq Global Market US USD 06. Feb 2014
DB RTI Common Stock Deutsche Boerse AG DE EUR 06. Feb 2014
BRSE RTI Common Stock Berne Stock Exchange CH CHF 06. Feb 2014
Number of employees
Current staff
Staff numbers
193
Revance Therapeutics employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 13:23
End of day share price update: 2020/04/07 00:00
Last estimates confirmation: 2020/04/01
Last earnings filing: 2020/02/26
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.